Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2751
Ecovyst
ECVT
$1.1B
| $675K | ﹤0.01% |
51,000
-84,200
| -62% | -$989K |
2019 Q1
5 quarters
|
|
|
LITB
2752
LightInTheBox
LITB
$59M
| $673K | ﹤0.01% |
127,737
+50,700
| +66% | +$242K |
2014 Q4
22 quarters
|
|
2753
Traws Pharma
TRAW
$6.84M
| $672K | ﹤0.01% |
+3,166
| New | +$484K |
2020 Q2
0 quarters
|
|
2754
Invesco S&P SmallCap Low Volatility ETF
XSLV
$234M
| $670K | ﹤0.01% |
19,800
-1,600
| -7% | -$53.1K |
2019 Q2
4 quarters
|
|
|
ATXS
2755
DELISTED
Astria Therapeutics
ATXS
| $669K | ﹤0.01% |
17,341
+7,953
| +85% | +$283K |
2017 Q1
13 quarters
|
|
|
VBIV
2756
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $666K | ﹤0.01% |
7,163
-4,264
| -37% | -$235K |
2020 Q1
1 quarter
|
|
|
KWY
2757
Kingsway Corp
KWY
$272M
| $665K | ﹤0.01% |
297,142
+32,682
| +12% | +$65K |
2014 Q2
24 quarters
|
|
|
AGEN
2758
Agenus
AGEN
$346M
| $664K | ﹤0.01% |
8,613
-15,320
| -64% | -$917K |
2019 Q3
3 quarters
|
|
|
ACCS
2759
ACCESS Newswire
ACCS
$17.6M
| $663K | ﹤0.01% |
+65,338
| New | +$658K |
2020 Q2
0 quarters
|
|
|
NBEV
2760
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
| $663K | ﹤0.01% |
+433,590
| New | +$647K |
2020 Q2
0 quarters
|
|
|
GORV
2761
DELISTED
Lazydays
GORV
| $662K | ﹤0.01% |
+2,533
| New | +$370K |
2020 Q2
0 quarters
|
|
2762
Marker Therapeutics
MRKR
$16.2M
| $662K | ﹤0.01% |
31,962
+8,492
| +36% | +$186K |
2019 Q4
2 quarters
|
|
2763
Vanguard Consumer Discretionary ETF
VCR
$5.83B
| $660K | ﹤0.01% |
+3,300
| New | +$595K |
2020 Q2
0 quarters
|
|
2764
iShares Morningstar Growth ETF
ILCG
$3.27B
| $657K | ﹤0.01% |
+14,000
| New | +$608K |
2020 Q2
0 quarters
|
|
|
ATRS
2765
DELISTED
Antares Pharma, Inc.
ATRS
| $653K | ﹤0.01% |
237,528
-1,129,086
| -83% | -$3.15M |
2019 Q1
5 quarters
|
|
2766
Vanguard S&P 500 ETF
VOO
$1.06T
| $652K | ﹤0.01% |
2,300
-2,800
| -55% | -$754K |
2019 Q4
2 quarters
|
|
2767
ImmuCell
ICCC
$89M
| $651K | ﹤0.01% |
137,672
+19,800
| +17% | +$86.3K |
2013 Q2
28 quarters
|
|
|
PHLT
2768
DELISTED
Performant Healthcare Inc
PHLT
| $650K | ﹤0.01% |
995,939
+33,200
| +3% | +$22.9K |
2013 Q4
26 quarters
|
|
|
AINC
2769
DELISTED
Ashford Inc.
AINC
| $649K | ﹤0.01% |
63,924
+4,941
| +8% | +$40.9K |
2016 Q2
16 quarters
|
|
2770
J. Jill
JILL
$364M
| $647K | ﹤0.01% |
187,084
+42,323
| +29% | +$115K |
2018 Q3
7 quarters
|
|
|
AFBI
2771
DELISTED
Affinity Bancshares
AFBI
| $646K | ﹤0.01% |
70,272
-22
| -0% | -$183 |
2018 Q1
9 quarters
|
|
2772
Tenax Therapeutics
TENX
$70M
| $646K | ﹤0.01% |
446
+83
| +23% | +$122K |
2017 Q4
10 quarters
|
|
2773
Dare Bioscience
DARE
$15.2M
| $645K | ﹤0.01% |
54,340
+37,589
| +224% | +$461K |
2018 Q1
9 quarters
|
|
2774
Direxion Daily MSCI Emerging Markets Bear 3X ETF
EDZ
$28.7M
| $641K | ﹤0.01% |
+2,450
| New | +$859K |
2020 Q2
0 quarters
|
|
2775
Build-A-Bear
BBW
$315M
| $639K | ﹤0.01% |
293,079
-75,403
| -20% | -$162K |
2013 Q2
28 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.